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In utero transplantation (IUT) is being pursued as a treatment for hematological and other kinds of birth defects ( Table 1 ). The allure of IUT is that early treatment may circumvent many of the problems associated with postnatal transplantation or that postnatal treatment can be eased by prenatal therapy. Cells can be delivered prior to full development of the fetal immune system without need for matching of major histocompatibility (MHC) antigens. Chorionic villus sampling makes the detection of genetic disease feasible by the end of the first trimester, 1 which provides sufficient time for transplantation prior to maturation of the thymus and the rapid accumulation of T cells in the fetus at the beginning of the second trimester of gestation. 2 The small size of the fetus obviates the need for a large graft. Thus, finding suitable donor tissue for IUT is less difficult than for postnatal transplantation. Engraftment of stem cells during fetal life allows for expansion of the donor cells along side the fetus' own cells leading to the development of chimerism. During the period of engraftment, the fetus remains protected from microbial and viral infections within the womb. Prenatal treatment also has the potential to prevent or ameliorate the effects of disease that threaten the health of the fetus or neonate even before symptoms of the disease manifest.
IUT has been used to successfully treat fetal patients with immunodeficiency disorders, but attempts at treating other types of disorders have not been as successful due, primarily, to the low levels of chimerism achieved. Indeed, many of the diseases that would benefit from hematopoietic stem cell transplantation that are listed in Table 1 require a high level of donor cell engraftment to provide a therapeutic effect. The main obstacle to engraftment appears to be the presence of the fetus' own cells, since no cytoablation is used prior to transplantation. The ability of the fetus' nascent immune system to reject foreign cells may have also been underestimated. [3] [4] [5] [6] [7] [8] Low engraftment followed by rejection from fetal NK-and T-cells may provide the one-two punch that has doomed many fetal transplant efforts.
The solution to poor engraftment may lie in the composition of the grafts. It is interesting to note that many of the early animal studies were successful in achieving clinically significant levels of chimerism (reviewed in Crombleholme et al 9 ) , whereas recent studies in a diversity of animal species have indicated a greater resistance to engraftment in recipients with a healthy stem cell compartment. A possible explanation is with the improvements and greater availability of methods for the isolation of stem cells and progenitors that cells important for engraftment, such as T cells, have been more thoroughly removed from the graft. Perhaps, in an effort to avoid graft-versus-host disease (GvHD) and reduce graft size we may have tried too hard to clean the grafts of accessory cell populations. Recent efforts at increasing engraftment and inducing donor-specific tolerance in animal models are reviewed as well as the clinical history of IUT. I am aware of over 45 attempts to use IUT to treat a variety  of hematopoietic and nonhematopoietic diseases, which are  summarized in Tables 2-4 .
Clinical experience with IUT

Immunodeficiencies
IUT has been most successful in treating immunodeficiencies that affect the production of lymphocyte populations (Table 2 ). In the first such case, bare lymphocyte syndrome was treated with IUT and postnatal booster transplants. 10, 35 The patient developed split chimerism with only the T cells coming from the donor. Although immune reconstitution was incomplete, the patient was reported to remain healthy for 11 years. 10 The patient received an additional transplant in an effort to correct the persistent cellular defects but complications resulted in death.
Split chimerism was also observed when treating severe combined immunodeficiency (SCID) by IUT ( Table 2 ). Xlinked SCID is characterized by a lack of T-and NK-cells resulting from mutation in CD132, the common cytokine receptor g-chain. T-cell reconstitution has been observed in each of the five cases of X-linked SCID transplanted in utero as well as NK-cell reconstitution when examined. Importantly, T cell reconstitution in X-linked SCID and in one case of SCID resulting from mutation of the interleukin-7 receptor a chain (IL7RA) was shown to be polyclonal, arising from T cells that have developed in the recipient rather than expansion of mature T-cells present in the graft. 15 T-cell reconstitution was also seen in a case of SCID with NK cells (T
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B cell function in this case was found to be normal based on examination of immunoglobulin levels and response to vaccination. 17 Thus, IUT for SCID can result in rapid restoration of normal humoral immune function, demonstrating one potential advantage of prenatal therapy over postnatal transplantation, which can result in a substantial delay in immune reconstitution. 36 The split chimerism that develops in T À B þ NK À/ þ SCID patients illustrates the difficulty donor stem cells face in engrafting even an immunodeficient fetus. Significant stem cell engraftment should lead to myeloid and B-cell chimerism but, at best, only low-level engraftment has been noted for these lineages. The conclusion is that successful immune reconstitution in SCID patients is believed to be the result of low-level stem cell engraftment that expands to fill the vacancies in the host's lymphopoietic system. Thus, the thymus is likely comprised predominantly of donor cells in these patients. The degree of donor hematopoiesis that occurs in the bone marrow is likely very low, but has not been studied in detail.
A number of other kinds of immunodeficiency disorders appear more resistant to engraftment by prenatal transplantation. SCID patients with a B-cell deficiency (Omenn syndrome) have not fared as well after IUT as other forms of SCID. Since the cellular deficit is quite large in these patients, the results appear counter-intuitive to what we expect from IUT. The likely explanation is that the cellular deficits in T À B À SCID occur too late in hematopoietic development to offer an advantage to donor stem cells. 15 This same explanation fits other cases were IUT has failed to produce significant chimerism. Both Chediack-Higashi syndrome and chronic granulomatous disease (CGD) affect the function rather than the production of hematopoietic cells and, thus, donor stem cells have no space to engraft or growth advantage over host stem cells in these diseases. For example, my colleagues and I at the University of California San Francisco transplanted one fetus with CGD with a quantity of purified paternal stem-cells estimated to be 30-fold more than present in the fetus itself but which resulted in no detectable engraftment. 7 Thus, even an abundance of donor stem cells does not appear sufficient to dislodge the fetus' resident hematopoietic system.
Hemoglobinopathies and Rh disease
IUT has been attempted in 20 cases of hemoglobinopathies or Rh antigen isoimmunization with little or no clinical benefit ( Table 3 ). The potential for prenatal death motivated the use of IUT in three cases of a-thalassemia. Although low-level donor chimerism was observed in two cases, the levels of donor cells were insufficient to ameliorate the disease. Lack of sufficient chimerism was also the outcome in the cases of b-thalassemia, sickle cell anemia and Rh antigen isoimmunization treated by IUT. Many of the transplant attempts occurred after the end of the first trimester, when the fetus had developed T cells, and may have been thwarted by the fetal immune system. The lack of space or competitive advantage for the donor stem cells was also likely to blame for the insufficient engraftment observed.
Although normal stem cells do not have a competitive advantage in thalassemic recipients, once produced normal erythrocytes do have a significant advantage over the thalassemic red cells. Thus, high levels of chimerism may not be needed to treat thalassemia, as the donor-derived stem cells are likely to disproportionately contribute to the pool of circulating erythrocytes. Indeed, experiments performed in b-thalassemic mice have had some measure of success in generating enough chimerism to ameliorate anemia in these animals. [37] [38] [39] It is estimated that chimerism levels of 10-20% are required to significantly diminish the effects of thalassemia. 40 To achieve these levels of chimerism, future therapy for hemoglobinopathies may depend on a strategy of combining prenatal transplantation to induce low-level chimerism and immune tolerance followed by postnatal transplant from the same donor tissue to boost the level of chimerism. Diminished T-cell responses towards donor cells were noted in two cases of IUT for red cell disorders (Table 3) , one transplant performed for athalassemia 22 and another performed for Rh-antigen isoimmunization. 30 If immune responses towards donor cells can be reliably diminished by IUT, then postnatal transplantation may be achieved without the need for immunosuppression.
Enzyme storage and other diseases
Hematopoietic stem cell transplantation can be considered a therapy for a number of enzyme storage diseases. IUT has a Developmental ages originally reported have been increased by 2 weeks to convert from a gestational timeline beginning at fertilization/conception to gestational age beginning at the time of last menstruation.
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been attempted in a number of such cases but has failed to improve the clinical course for these patients (Table 4 ). An insignificant level of chimerism remains the obstacle for prenatal treatment for such diseases. The potential for IUT to result in immune tolerance was the rationale behind transplanting fetal liver in the case of Hemophilia A. 10 Interestingly, relatively high levels of chimerism were reported in the first year of life (Table 4) . However, the goal of the transplant was not to directly cure the disease but to expose the fetus to factor VIII such that future treatment with factor VIII would not result in immunization. The outcome of this effort is pending.
A more direct approach to treating hemophilia as well as other diseases is to develop IUT using nonhematopoietic stem cell populations. Many genetic diseases affect the function of hepatocytes. Hepatocyte or hepatic stem cell transplantation may be a viable treatment for such diseases. Some success in hepatocyte engraftment has been reported in factor X-deficient mice. 41 Hepatocyte chimerism has also been achieved in non-human primates transplanted with fetal hepatocytes. 42, 43 Human mesenchymal stem cells have also been shown to engraft numerous tissues when transplanted in fetal sheep. 44 Mesenchymal stem cells derived from fetal liver have also been transplanted in a case of osteogenesis imperfecta resulting in the detection of 5% donor-derived osteoblasts at 8 months of age (Table 4) . 34 Further results of this case and another two cases of osteogenesis imperfecta treated by IUT (Dr F Porta, personnel communication, September 2004) are awaited to determine if the engraftment barriers to mesenchymal stem cells are less than those for hematopoietic stem cells.
A choice of grafts for IUT
The small size of the fetal patient and the unique properties of fetal cells have made for variable choices in the source of donor cells for IUT. Advantages and disadvantages of different sources of tissues are summarized in Table 5 .
Fetal tissue
Fetal tissues collected from elective abortions have been used in many cases of IUT. Fetal liver from first trimester fetuses, and in some cases thymic tissue, 10 has been used because of its low potential to cause GvHD and the developmental match between these tissues and the patient. Although it is recognized that adult stem cells will engraft in the fetal environment, 45 notable differences exist between the biological properties of fetal and adult stem cells. 46 A number of animal studies have indicated an advantage to using fetal grafts for IUT, 39, [47] [48] [49] albeit the use of fetal tissues alone does not appear to overcome the major obstacles preventing clinically significant engraftment. Although the number of stem cells present in first trimester liver is low compared to other sources of stem cells, the liver does represent the major reservoir of stem cells that provide life-long hematopoiesis. The brief proliferative history of fetal stem cells may be more important in IUT than the absolute number of stem cells transplanted. Fetal liver and Developmental ages originally reported have been increased by 2 weeks to convert from a gestational timeline beginning at fertilization/conception to gestational age beginning at the time of last menstruation.
bone marrow from abortions performed between 15 and 24 weeks' gestation offer a greater number of cells for transplantation but also contain a significant number of T cells. 50, 51 The number of stem cells available from second trimester liver and bone marrow exceeds that of a typical umbilical cord blood harvest and offers the possibility of multiple transplants from a single fetal tissue. 51 The availability of fetal tissue is subject to variable legal restrictions limiting its use. A number of groups interested in IUT have established fetal liver banks [50] [51] [52] [53] [54] [55] [56] and the number of transplants performed using these tissues is a testament to the safety of using fetal tissue for transplantation (Tables 2-4) .
Umbilical cord blood
Neonatal umbilical cord blood had not been used for IUT because of concern for GvHD owing to the large number of T cells present in blood. The number of T cells that can be safely transplanted into a fetus and the effects of the developmental age of the donor T cells on the risk of GvHD in a fetus has not been clearly resolved. Two cases of fetal blood transplants have occurred (Table 3) , but these cases offer no information as to the safety of using neonatal blood. The use of banked neonatal blood from sibling donors offers the possibility of an MHC-matched transplant using tissue that has developmental properties intermediate to those of fetal and adult tissues.
Bone marrow and peripheral blood stem cells
Bone marrow from a parent or sibling that has been depleted of T cells and/or enriched for CD34 þ cells has been successfully used in a number of cases IUT (Tables 2-4 ). The advantages of using familial bone marrow or peripheral blood stem cells are that the family members are likely motivated donors. Sibling donors offer the possibility of an MHC-matched transplant and use of a living relative offers the potential for subsequent harvest for booster transplants. The disadvantage is that ontogenic differences may give the fetus' cells a competitive advantage over the adult cells. The proliferative history of the adult especially when only low engraftment is achieved. Since related donors may also be carriers of the same disease that afflicts the fetus, the implications in terms of the graft's long-term viability of this carrier status must be considered before using a familial donor.
Future directions in IUT
It was hypothesized that stem cells transplanted into a fetus during the time of bone marrow seeding would join the procession of host stem cells in the circulation and mix with host tissues resulting in chimerism. A good amount of evidence argues that the seeding of the host hematopoietic tissues in the absence of cytoablation is an inefficient process, but many questions remain as to the exact confluence of conditions that limit engraftment (Table 6 ). For instance, perhaps the emergent immune system may contribute to graft rejection in patients not suffering from an immunodeficiency. One area of investigation to improve engraftment is in the use of donor T cells to provide an advantage to the donor tissue. A strategy of in utero tolerance induction and postnatal booster transplantation is also being studied as a method to increase engraftment levels.
The role of donor T cells
T cells may become the friends rather than the foes of IUT. The tiny size of the fetal patient, approximately 25-100 g at 14 weeks' gestation, 59 has enforced the concern that donor T cells may cause GvHD. To avoid GvHD, my colleagues and I have followed a guideline that no more than 5 Â 10 5 T cells/kg be administered. 7 However, there is evidence to suggest that the fetus can tolerate a dose of T cells higher than the threshold we had set. A study in nonhuman primates suggests a threshold around 1 Â 10 7 T Table 6 Some unresolved questions and future directions in IUT Determine mechanisms by which the fetus resists engraftment Define stem cell/progenitor population that needs to be dislodged or ablated to allow engraftment. Which precursors in the hematopoietic tissues prevent stem cell engraftment? Do cellular barriers limit engraftment of other tissue types such as hepatocytes, mesenchymal stem cells or myocytes? Which genetic diseases result in host tissues being more amenable to engraftment?
Determine Determine if IUT can be used to induce tolerance for single proteins. Does in utero exposure to missing self-antigens prevent the development of antibody associated with long-term enzyme/protein-replacement therapy? What is the best method for the delivery of proteins to the fetus for the purpose of tolerance induction? Can the fetal peritoneum be used to harbor cells engineered to produce desired proteins as a means to provide continuous in utero delivery? cells/kg at which clinically significant levels of chimerism were detected. 60 This study indicated a minimum dose above 1 Â 10 6 T cells/kg to achieve 1% chimerism and observed GvHD at a dose above 1 Â 10 8 T cells/kg. An earlier study in sheep had reported similar findings. 61 The presence of allogeneic donor T cells has also improved engraftment in murine models of IUT 62, 63 when compared to the very low levels of chimerism achieved in the absence of T-cell response favoring the donor cells. [64] [65] [66] [67] Clinical experience also points to the benefits of a higher dose of donor T cells. Reported cases of IUT for globoid cell leukodystrophy (Table 4 ) suggest doses ranging from 2 to 4 Â 10 7 T cells/kg can be tolerated and may lead to low level chimerism. 32 However, a fetus transplanted with 42.5 Â 10 8 T cells/kg died from overwhelming engraftment. 32 These findings encourage further work to determine the dose of T cells that can be safely administered to a fetus and how donor T cells may promote engraftment (Table 6 ).
Development of immune tolerance
Recent focus has been on using IUT to promote donorspecific tolerance for subsequent postnatal transplantation (Table 6 ). Tolerance has been indicated in a few human cases of IUT in addition to the successfully treated cases of SCID (Tables 2-4 ). In utero tolerance induction could be combined with postnatal transplantation, using the same donor source, to increase chimerism to desired levels. This strategy has been tested in mice were secondary transplantation has increased chimerism levels from about 0.2% to approximately 5% in one study. 68 In another study, IUT was followed by postnatal infusion of lymphocytes that converted low-level chimerism to complete allogeneic engraftment in which GvHD was only rarely observed. 69 Translation of these results to the clinic would find IUT to be an effective therapy for many of the diseases listed in Table 1. IUT has also been used to promote tolerance for postnatal solid organ transplantation. 70 Tolerance was induced in swine by IUT of partially T cell depleted bone marrow. Tolerant swine received kidney transplants, from donors with MHC antigens matching the bone marrow donors, and accepted these organs without the need for long-term immunosuppression. Tolerance induction appears to require at least the presence of low-level chimerism. 71 In mice, the presence of donor T cells has improved the likelihood of tolerance induction. 66, 67 The peritoneal cavity of mice has also been found to harbor high numbers of donor cells. The presence of donor cells in the peritoneum was found to correlate with tolerance induction, suggesting that the peritoneum can be used as a reservoir for cells to introduce foreign antigens to a fetus.
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Conclusions
The deleterious effects of many birth defects begin before birth or soon afterwards. The technology of prenatal diagnosis continues to improve allowing for greater numbers of genetic and developmental defects to be diagnosed early in gestation. IUT has the potential to treat a large number of these diseases. IUT should be considered a viable form of treatment for T À B
þ SCID in its current form. Encouraging insights from recent animal studies suggest that the barriers to donor cell engraftment can be breached opening the possibility for wider clinical application of IUT in the future.
